XML 60 R46.htm IDEA: XBRL DOCUMENT v3.23.2
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 164 Months Ended
Nov. 30, 2009
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Dec. 31, 2022
License Agreements              
Total revenues   $ 954,610 $ 911,397 $ 1,763,283 $ 1,644,632    
Product royalty revenues              
License Agreements              
Total revenues   127,605 117,546 243,041 239,960    
JAKAFI              
License Agreements              
Total revenues   682,384 597,673 1,262,353 1,142,137    
Milestone and contract revenues              
License Agreements              
Total revenues   0 130,000 0 135,000    
Novartis              
License Agreements              
Royalties payable   310,300   310,300   $ 310,300 $ 253,500
Novartis | JAKAVI | Non-US              
License Agreements              
Royalties payable on net sales   90,400 83,700 167,100 154,600    
Novartis | JAKAFI | UNITED STATES              
License Agreements              
Royalties payable on net sales   33,500 29,300 56,900 51,000    
Novartis | Milestone and contract revenues              
License Agreements              
Total revenues   0 60,000 0 60,000    
Novartis | TABRECTA PROD SERV | Non-US              
License Agreements              
Royalties payable on net sales   $ 4,800 $ 3,600 $ 9,000 $ 7,100    
Minimum | Novartis | JAKAVI              
License Agreements              
Royalty payments on future global net sales (as a percent)       12.00%      
Maximum | Novartis | JAKAVI              
License Agreements              
Royalty payments on future global net sales (as a percent)       14.00%      
Development Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           157,000  
Development Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement $ 174,000            
Regulatory Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           340,000  
Regulatory Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement 495,000            
Commercialization Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           $ 200,000  
Commercialization Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement 500,000            
Development and Regulatory Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement $ 75,000